 NEW YORK, May 3, 2021 PRNewswire -- DLA Piper represented Akoya Biosciences, Inc. Nasdaq: AKYA in its recent initial public offering of 7,567,000 shares of its common stock at a price of 20 per share, including the exercise of the underwriters option to purchase 987,000 shares of common stock, less underwriting discounts and commissions. Akoya offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. 